Lack of therapeutic efficacy of an antibody to a4b7 in SIVmac251-infected rhesus macaques

29Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent study reported that administration of an antibody against a4b7 induced durable virologic control after ART discontinuation in 100% of rhesus macaques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop codon in nef. We performed similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In animals that initiated ART during either acute or chronic infection, anti-a4b7 antibody infusion had no detectable effect on the viral reservoir or viral rebound after ART discontinuation. These data demonstrate that anti-a4b7 antibody administration did not provide therapeutic efficacy in the model of pathogenic SIVmac251 infection of rhesus macaques.

Cite

CITATION STYLE

APA

Abbink, P., Mercado, N. B., Nkolola, J. P., Peterson, R. L., Tuyishime, H., McMahan, K., … Barouch, D. H. (2019). Lack of therapeutic efficacy of an antibody to a4b7 in SIVmac251-infected rhesus macaques. Science, 365(6457), 1029–1033. https://doi.org/10.1126/science.aaw8562

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free